As to the 29 patients affected by both bilateral RAMLs and other TSC-related tumors, which met the clinical criteria for TSC, 18 (62.1%) alterations in TSC1/2 were observed (Table 2). This evidence concerns the gene TSC1 and tuberous sclerosis.